tirzepatide death (Zepbound) showed improved kidney function in obese patients with both chronic kidney disease and #heartfailure with preserved ejection fraction, highlighting its potential to address this high-risk patient population. Read more: https Tirzepatide noninferior to dulaglutide for

The functional mechanisms linking specific microbial taxa or microbial-derived metabolites to endocrine and metabolic disturbances also remain incompletely understood

IV use could also be needed when there are gastrointestinal complications leading to the need for the liquid to bypass the stomach

If you have lost less than 5% of body weight after six months at maximum dose with good adherence, you may be a non-responder

The cumulative effect over months is substantial

Decisions should be individualized: consider the procedures urgency, the patients diabetes control, and the type of anesthesia planned

There are not enough human safety studies